booksshare.net -> -> -> . -> " " -> 40

- .

. .: , 2007. 608 c.
ISBN 5-98657-009-
( ): pharmazeutischewirkstoffe1982.djvu
<< 1 .. 34 35 36 37 38 39 < 40 > 41 42 43 44 45 46 .. 345 >>

USP 3 529 060 (Warner Lambert; ert. 15.9.1970; I-Prior. 1.3.1967).
A. Ercoli et al.T J. Med. Chem. 15,783 (1972).
Weiteres Verfahren:
DOS 2 340591 (Glaxo; Anm. 10.8.1973; GB-Prior. 11.8.1972).
Galenische Zubereitung:
USP 3 749 773 (Warner Lambert; ert. 31.7.1973; Prior. 25.2.1971).
D: Euvaderm®(Sasse) USA: Benisone®(Warner Chilcott)
Parbetan® (Parke-Davis) Flurobate® (Texas Pharmacal)
GB-. Bebate® (Warner) Uticort™ (Parke-Davis)
I: Beben® (Vister)
Betamethason (s. S. 95)
Orthobenzoesaure-
trimethylester
Betamethasondipropionat - Betamethasondivalerat В 99
Betamethasondipropionat 5593-20-4
Glucocorticoid
9-fluoro-ll/S ,17,21-trihydroxy-16/? -methylpregna-l,4-diene-3,20-dione-17,21-dipropionate
HO-CH2
1. Н5Сг-С-0СгН5/^НзС-^>-50эН^ OC2H5
2- CH3COOH/H2Q_
t Orthoproptonsauretriethylester
HsC2—CO—Cl / [pyridm]
Proptonsaure-
chlond
ИО-СН2
-O-CO-C2H5
СНз
H5C2-CO-0-CH2,
Betamethasondipropionat
USP 3 312 591 (Glaxo; ert. 4.4.1967; GB-Prior. 10.5.1963, 28.1.1964).
USP 3 312 590 (Glaxo; ert. 4.4.1967; GB-Prior. 11.6.1963,28.1.1964). DBP 1 443 957 (Glaxo; Anm. 10.6.1964; GB-Prior. 11.6.1963, 28.1.1964). Ubersicht:
М. C. Ferrante, В. C. Rudy, Anal. Profiles Drug Subst. 6,43 (1977).
D: Diprogenta® (Byk Essex)-Komb.
Diprosone® (Byk Essex)
F: Diprosone® (Unilabo)
Diprosone®Neomycin (Unilabo)-Komb. Diprostene® (Cetrane)-Komb. DiprosaHc® (Unilabo)
GB: . Diprosalic® (Schering)
I: Diprosone® (Essex)
USA: Diproderm® (Schering)
Diprogert* (Schering)-Komb. Diprosone® (Schering) Vanceril® (Schering)
Betamethasondivalerat 38196-44-0
Glucocorticoid
9-fluoro-llj6.17,21-trihydroxy-16£-methylpregna-l,4-diene-3,20-dione-17,21-dipentanoate ho-ch2
<4^0
H0^ ^jJ..O-CO-(CH2)3-CH3
h|>—снз
Betamethasonvaterat (s. S. 101)
+ нэс-(сн2ь-со—c\
Valeriansaurechlorid
Pyndin
НзС-(СН2)з-С0-0-СН2,
■ 0-C0-{CH2)3-CH3 СНэ
Betamethasondivalerat
100 В Betamethasondivalerat - Betamethasonphosphat
USP 3 312 591 (Glaxo; ert. 4.4.1967; GB-Prior. 10.5.1963, 28.1.1964).
USP 3 312590 (Glaxo; ert. 4.4.1967; GB-Prior. 11.6.1963, 28.1.1964).
DBP 1443 957 (Glaxo; ert. 10.6.1964; GB-Prior. 11.6.1963,28.1.1964). vgl. Betametasondipropionat
I: Betadival® (Fardeco) Diprosone® Creme (Essex)
Betamethasonphosphat 360-36-4 Glucocorticoid
151-73-5 Di-Na-Salz
9-fluoro-l 1/?, 17,21-trihydroxy-16/?-methylpregna-l,4-diene-3,20-dione-21-phosphate
Betamethason
(s. S. 95)
1 НэС-SChCl/[Pyridin]
2. Nal/Acetcn
3. AgH2POt/NaOH
^ [Hi_
). Wethansulfonylchlcrid
2 Natrumjodid
3 Silbefhydrogenphosphat
(НО)гР—О—CH2 л
Betamethasonphosphat
GB-P 913 941 (Merck & Co.; Laufzeit ab 1959; USA-Prior. 1958). Weitere Verfahren:
USP 2 939 873 (Merck & Co.; ert. 1960; Prior. 1959).
DOS 2 225 658 (I. Villax; Anm. 26.5.1971; P-Prior. 5.6.1971).
DBP 1 134 075 (Merck AG; Anm. 1959).
Wafirige Losung, durch l-Mercapto-2,3-propandiol stabilisiert:
DBP 2021446 (Gruppo Lepetit; Anm. 2-5.1970; I-Prior. 7.5.1969).
D: Betnesol® Past. (Glaxo)
Betnesol® Rekt. (Glaxo)
CeIestan®sol. (Byk-Essex)
F: Betnesol® (Glaxo)
Diprostene® (Cetrane)-Komb.
GB: Betnesol® (Glaxo)
Betnesol®N (Glaxo)-Komb.
I: Bentelan® (Glaxo)
BenteJan® Control (Duncan) Betafluorene® Gocce (Lepetit) Betameson® (Aristochimica) Celestone®Av. Col., Iniett.,Unguento Oft. (Essex)
Emilan® (Perkins)
Pancisone® (Ita)
J: Linosal® (Wakamoto)
USA: Celestone® Phosp.Inj. (Schering)-Komb. Solo-Celestone® (Schering)
Betamethasonvalerat - Betanidin В 101
Betamethasonvalerat 33755-46-3 Glucocorticoid
9-Ниого-11Д 17,21-trihydroxy- 16/3-methylpregna-l,4-diene-3,20-dione-17-pentanoate
HO-CH2.
Bctamethason
(s. S 95)
OCHi
i нэс-1сн:)э-с-оснз! aa3n
оснз
2. CH30H/H;0/H;S0t_
1 Orthovalenansaure- 0-To(uolsulforsaure trimethyiesier
USP 3 312 590 (Glaxo; ert. 4.4.1967; GB-Prior. 11.6.1963,28.1.1964). USP 3 312 591 (Glaxo; ert. 4.4.1967; GB-Prior. 10.5.1963, 28.1.1964). Weiteres Verfahren;
DOS 2 055 221 (Lab. Chim. Farm. Blasina; Anm. 10.11.1970).
DOS 2 340591 (Glaxo; Anm. 10.8.1973; GB-Prior. 11.8.1972).
DOS 2 431 377 (Lark; Anm. 29.6.1974; T-Prior. 4.1.1974). Dermatologische Anwendung:
SA-P 7 700 678 (S. Fourie et al., Anm. 7.2.1977).
FP-M 5399 (P. Temime; Anm. 14.10.1965).
Belg-P 829197 (L. Grosjean; Anm. 16.5.1975).
D: Betnesol®VN, *.,mite“ (Glaxo)-Komb.
Celestan®V, -crinaie (Byk-Essex)
Celestan®V mit Neomycin (Byk-Essex)-Komb. Celestan®V mit Sulmycin (Byk-Essex)-Komb. Procto-Celestan® (Byk-Essex)-Komb. Recto-Betnesol® (Glaxo)-Komb.
F: Betneval® (Glaxo-Evans)
Celestoderm (Cetrane)
GB: Betnelan®V (Glaxo)
Betnovate® (Glaxo)
Bextasol® (Glaxo)
Retenema® (Glaxo-Evans)
I; Celestoderm-V (Essx)
Cortico Lg (Lancet)
Dermovaleas (Valeas)
Ecoval-70 (Glaxo)
Stranoval (Glaxo)
J: Betnevate®N (Daiichi)-Komb. Dermosol® (Iwaki)
Hormezon (Tobishi Jakuhin Kogyo) Muhibeta®V (Ikeda Mohando) Rinderon®V (Shionogi)-Komb. Rinderon®VA (Shionogi)-Komb. Rinderon®VG (Shionogi)-Komb. USA; VaJisone® (Schering)
<< 1 .. 34 35 36 37 38 39 < 40 > 41 42 43 44 45 46 .. 345 >>

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

, ?
2009 BooksShare.
.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed